Ratings Traws Pharma, Inc.

Equities

TRAW

US68232V8019

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.6207 ^USD	-1.87%		-7.50%	-16.75%

Apr. 04	North American Morning Briefing : Focus Turns to -2-	DJ
Apr. 04	Traws Pharma, Inc. Announces Chief Executive Office Changes	CI

Strengths

For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
The group usually releases upbeat results with huge surprise rates.

Weaknesses

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
TRAWS PHARMA, INC.	-16.75%	13.34M	-
IQVIA HOLDINGS INC.	+1.51%	42.59B	B
MODERNA, INC.	+8.57%	40.65B	B-
LONZA GROUP AG	+49.22%	40.57B	A
CELLTRION, INC.	-12.36%	26.77B	C
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B	B-
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B	B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B	C+
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes